Read More Pharma Industry News Ascletis Pharma advances ASC36 into clinical development, betting on oral amylin peptides for obesity Ascletis Pharma Inc. moves ASC36 into clinical development, signalling a strategic push into oral amylin peptides for obesity. Find out what this means next. byVenkateshFebruary 11, 2026